These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 25293772)

  • 41. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
    Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brentuximab vedotin in CD30
    Stranzenbach R; Dippel E; Schlaak M; Stadler R
    Br J Dermatol; 2017 Dec; 177(6):1503-1509. PubMed ID: 28703284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
    Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Yang Y; Sievers EL; Kennedy DA; Shustov A
    J Clin Oncol; 2012 Jun; 30(18):2190-6. PubMed ID: 22614995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
    Goyal SD; Bartlett NL
    Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-CD30 Antibodies for Hodgkin lymphoma.
    Foyil KV; Bartlett NL
    Curr Hematol Malig Rep; 2010 Jul; 5(3):140-7. PubMed ID: 20446121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brentuximab vedotin for treatment of systemic T-cell lymphoma.
    Chihara D; Oki Y
    Expert Opin Biol Ther; 2014 Oct; 14(10):1519-26. PubMed ID: 25200691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
    Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
    Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brentuximab vedotin.
    van de Donk NW; Dhimolea E
    MAbs; 2012; 4(4):458-65. PubMed ID: 22684302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brentuximab vedotin.
    Younes A; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2012 Jan; 11(1):19-20. PubMed ID: 22212672
    [No Abstract]   [Full Text] [Related]  

  • 54. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
    Koga Y; Sekimizu M; Iguchi A; Kada A; Saito AM; Asada R; Mori T; Horibe K
    Int J Hematol; 2020 May; 111(5):711-718. PubMed ID: 31960285
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
    Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
    Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
    J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
    Senter PD; Sievers EL
    Nat Biotechnol; 2012 Jul; 30(7):631-7. PubMed ID: 22781692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.
    Gibb A; Jones C; Bloor A; Kulkarni S; Illidge T; Linton K; Radford J
    Haematologica; 2013 Apr; 98(4):611-4. PubMed ID: 23065511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy.
    Gopal AK; Bartlett NL; Forero-Torres A; Younes A; Chen R; Friedberg JW; Matous JV; Shustov AR; Smith SE; Zain J; O'Meara MM; Fanale MA
    Leuk Lymphoma; 2014 Oct; 55(10):2328-34. PubMed ID: 24359243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
    Broccoli A; Pellegrini C; Di Rocco A; Puccini B; Patti C; Gini G; Mannina D; Tani M; Rusconi C; Romano A; Vanazzi A; Botto B; Carlo-Stella C; Hohaus S; Musto P; Mazza P; Molica S; Corradini P; Fama A; Gaudio F; Merli M; Gravetti A; Gritti G; Arcari A; Tosi P; Liberati AM; Pinto A; Pavone V; Gherlinzoni F; Naso V; Volpetti S; Trentin L; Goldaniga MC; Bonfichi M; De Renzo A; Schiavotto C; Spina M; Storti S; Carella AM; Stefoni V; Argnani L; Zinzani PL
    Haematologica; 2017 Nov; 102(11):1931-1935. PubMed ID: 28775121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.